Publications by authors named "Cui-Wei Lu"
Background: The clinical utility of in treating autism spectrum disorder (ASD) remains unclear. Therefore, this randomized, double-blind, placebo-controlled study aimed to explore the therapeutic effects and safety of BF839 in the treatment of pediatric ASD.
Methods: We examined 60 children aged 2-10 years diagnosed with ASD, and participants received either BF839 powder (10 g/bar with ≥10 CFU/bar of viable bacteria, two bars/day) or placebo for 16 weeks.